Spero Therapeutics, Inc. (SPRO) Stock

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is led by CEO Esther Rajavelu, employs 32 people, headquartered in US, publicly traded since 2017.

Spero Therapeutics, Inc. (SPRO) stock trades at $1.11 with a market capitalization of $64.64M. The stock is valued at a price-to-earnings (P/E) ratio of 8.50, price-to-book of 1.56, price-to-sales of 1.60. Over the past 52 weeks the stock has ranged between $1.08 and $3.08, and currently trades 64.0% below its 52-week high.

On profitability, Spero Therapeutics, Inc. generates a return on equity (ROE) of 16.17%, above the typical market range of roughly 12-15%, return on capital employed of 13.59%, an operating margin of 24.66%, a net profit margin of 17.18%.

Spero Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Spero Therapeutics, Inc. reported revenue of $0 rising to $60.0M. Compounded, revenue has grown 46.1% a year over five years, 7.0% over three, 25.0% over the last twelve months. Net profit rose to $9.0M.

Operating margin went from -9916.7% in 2016 to -0.0% in 2025, a gain of 9916.7 percentage points. The most recent net margin is 17.18%. On a trailing twelve-month basis to Jun '26, revenue is $43.0M and net profit $8.0M.

Borrowings stand at $3.0M, cash from operations was $-13.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -55.2% over five years, and was 15.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Spero Therapeutics, Inc. (SPRO) — frequently asked questions